Immunohistochemical evidence of insulin-like growth factor II in human small hepatocellular carcinoma with hepatitis C virus infection: Relationship to fatty change in carcinoma cells

Journal of Gastroenterology and Hepatology (Australia)

Volumn 12, Issue 3, 1997, Pages 224-228

  Sohda, Tetsuro ^a   Kamimura, Sehchiro ^a   Iwata, Kaoru ^a   Shijo, Hiroshi ^a   Okumura, Makoto ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

fatty change; hepatitis C virus; hepatocellular carcinoma; insulin like growth factor II

Indexed keywords

SOMATOMEDIN B;

ARTICLE; CLINICAL ARTICLE; HEPATITIS C VIRUS; HUMAN; LIVER CANCER; PRIORITY JOURNAL;

EID: 0030934030     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1997.tb00412.x     Document Type: Article

References (18)

1. Sporn MB, Todaro GJ. Autocrine secretion and malignant transformation of cells. N. Engl. J. Med. 1980; 303: 878-80.
2. Sporn MB, Robert AB. Autocrine growth factors and cancer. Nature 1985; 313: 745-7.
3. LeRoith D, Baserga R, Helman LJ, Roberts CT Jr. Insulin-like growth factors and cancer. Ann. Intern. Med. 1995; 122: 54-9.
4. D'Arville CN, Nouri-Aria KT, Johnson P, Williams R. Regulation of insulin-like growth factor II gene expression by hepatitis B virus in hepatocellular carcinoma. Hepatology 1991; 13: 310-15.
5. Su Q, Liu Y-H, Zhang J-F, Zhang S-X, Li D-F, Yang J-J. Expression of insulin-like growth factor II in hepatitis B, cirrhosis and hepatocellular carcinoma: Its relationship with hepatitis B virus antigen expression. Hepatology 1994; 19: 788-99.
6. Gibson JB, Sobin LH. Histological typing of tumors of the liver, biliary tract and pancreas. Geneva: World Health Organization, 1978.
7. Tobey TA, Greenfield M, Kraemer F, Reaven GM. Relationship between insulin secretion, very low density lipoprotein kinesis and plasma triglyceride levels in normotriglyceridemic man. Metabolism 1981; 30: 165-71.
8. Ingebritsen TS, Geelen MJH, Parker RA, Evenson KJ, Gibson DM. Modulation of hydroxymethylglutaryl Co-A reductase activity, reductase kinase activity, and cholesterol synthesis in rat hepatocytes in response to insulin and glucagon. J. Biol. Chem. 1979; 254: 9986-9.
9. 2O incorporation into fatty acids. FEBS Lett. 1978; 95: 326-30.
10. Edmondson HA, Steiner PE. Primary carcinoma of the liver: A study of 100 cases among 48 900 necropsies. Cancer 1954; 7: 462-503.
11. MaCauly VM. Insulin-like growth factors and cancer. Br. J. Cancer 1992; 65: 311-20.
12. Lamas E, Bail BL, Houssert C, Boucher O, Bréchot C. Localization of insulin-like growth factor-II and hepatitis B virus mRNAs and proteins in human hepatocellular carcinomas. Lab. Invest. 1991; 64: 98-104.
13. Yun K, Molenaar AJ, Fiedler AM et al. Insulin-like growth factor II messenger ribonucleic acids expression in Wilms tumor, nephrogenic rest, and kidney. Lab. Invest. 1993; 69: 603-15.
14. D'Errico A, Grigioni WF, Fiorentino M et al. Expression of insulin-like growth factor-II (IGF-II) in human hepatocellular carcinomas: An immunohistochemical study. Pathol. Int. 1994; 44: 131-7.
15. Maruhara Y, Ohneda A, Tadaki H et al. Hepatic steatosis and the elevated plasma insulin level in patients with endogenous hypertriglyceridemia. Metabolism 1975; 24: 653-64.
16. Yonei T, Tanaka M, Ozawa Y et al. Primary hepatocellular carcinoma with severe hypoglycemia: Involvement of insulin-like growth factors. Liver 1992; 12: 90-3.
17. Kotani K, Tsuji M, Oki A et al. IGF-II producing hepatic fibrosarcoma associated with hypoglycemia. Intern. Med. 1993; 32: 897-901.
18. Eastman RC, Carson RE, Orloff DG et al. Glucose utilization in a patient with hepatoma and hypoglycemia. J. Clin. Invest. 1992; 89: 1958-63.